Microbial biofilm formation: A need to act

Journal of Internal Medicine

Volumn 276, Issue 2, 2014, Pages 98-110

  Romling U ^a   Kjelleberg, S ^b   Normark, S ^a,c   Nyman, L ^d   Uhlin, B E ^e   Akerlund B ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

^d Pfizer AB   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic resistance; Bioinformatics; Cyclic di nucleotides; Device related infections; Extracellular matrix; Tissue infections

Indexed keywords

ANTIBIOTIC SENSITIVITY; BACTERIAL IMMUNITY; BIOFILM; BIOINFORMATICS; CATHETER INFECTION; DISEASE ASSOCIATION; EDITORIAL; INFECTION PREVENTION; INNATE IMMUNITY; NEOPLASM; NONHUMAN; PERSISTENT INFECTION; PHENOTYPE; PRIORITY JOURNAL; PROSTHESIS INFECTION; SOFT TISSUE INFECTION; SYSTEM ANALYSIS;

ANTIBIOTIC RESISTANCE; BIOINFORMATICS; CYCLIC DI-NUCLEOTIDES; DEVICE-RELATED INFECTIONS; EXTRACELLULAR MATRIX; TISSUE INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOFILMS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, PERIPHERAL; CATHETERS, INDWELLING; CONGRESSES AS TOPIC; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; EQUIPMENT CONTAMINATION; EVIDENCE-BASED MEDICINE; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERDISCIPLINARY COMMUNICATION; MICROBIOLOGY; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS;

EID: 84904245437     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12242     Document Type: Editorial

References (153)

1. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003; 57: 677-701.
2. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108.
3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
4. Høiby NA. Personal history of research on microbial biofilms and biofilm infections. Pathog Dis 2014; 70: 205-11.
5. Wolcott RD, Rhoads DD, Bennett ME et al. Chronic wounds and the medical biofilm paradigm. J Wound Care 2010; 19: 45-6, 48-50, 52-3.
6. Folkesson A, Jelsbak L, Yang L et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 2012; 10: 841-51.
7. Sahuquillo-Arce JM, Selva M, Perpinan H et al. Antimicrobial resistance in more than 100 000 Escherichia coli isolates according to culture site and patient age, gender, and location. Antimicrob Agents Chemother 2011; 55: 1222-8.
8. Stickler DJ. Crystalline biofilms on urinary catheters: clinical complications, structure, formation and attempts at control. Nobel Conference on Biofilm formation, its clinical impact and potential treatment. 28-30 August, 2013, Karolinska Institutet, Stockholm, Sweden, 2013.
9. Osmon DR, Berbari EF, Berendt AR et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: e1-25.
10. Sendi P, Zimmerli W. Diagnosis of periprosthetic joint infections in clinical practice. Int J Artif Organs 2012; 35: 913-22.
11. Hall-Stoodley L, Stoodley P, Kathju S et al. Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol 2012; 65: 127-45.
12. Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 2012; 272: 541-61.
13. Høiby N, Bjarnsholt T, Moser C et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2013.
14. Ghigo J-M. Identification of biofilm-associated biomarkers. Nobel Conference on Biofilm formation, its clinical impact and potential treatment. 28-30 August, 2013, Karolinska Institutet, Stockholm, Sweden. 2013.
15. Finkel JS, Mitchell AP. Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 2011; 9: 109-18.
16. Monds RD, O'Toole GA. The developmental model of microbial biofilms: ten years of a paradigm up for review. Trends Microbiol 2009; 17: 73-87.
17. Berk V, Fong JC, Dempsey GT et al. Molecular architecture and assembly principles of Vibrio cholerae biofilms. Science 2012; 337: 236-9.
18. Zhao K, Tseng BS, Beckerman B et al. Psl trails guide exploration and microcolony formation in Pseudomonas aeruginosa biofilms. Nature 2013; 497: 388-91.
19. Dueholm MS, Sondergaard MT, Nilsson M et al. Expression of Fap amyloids in Pseudomonas aeruginosa, P. fluorescens, and P. putida results in aggregation and increased biofilm formation. MicrobiologyOpen 2013; 2: 365-82.
20. Irie Y, Borlee BR, O'Connor JR et al. Self-produced exopolysaccharide is a signal that stimulates biofilm formation in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2012; 109: 20632-6.
21. Wilksch JJ, Yang J, Clements A et al. MrkH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 fimbriae expression. PLoS Pathog 2011; 7: e1002204.
22. Siegel BZ, Siegel SM, Chen J, LaRock P. An extraterrestrial habitat on Earth: the algal mat of Don Juan [correction of Jaun] Pond. Adv Space Res 1983; 3: 39-42.
23. Yildiz FH. Structure and function of Vibrio cholerae biofilm matrix. Nobel Conference on Biofilm formation, its clinical impact and potential treatment. 28-30 August, 2013, Karolinska Institutet, Stockholm, Sweden, 2013.
24. Yildiz F, Fong J, Sadovskaya I, Grard T, Vinogradov E. Structural characterization of the extracellular polysaccharide from Vibrio cholerae O1 El-Tor. PLoS One 2014; 9: e86751.
25. Skurnik D, Davis MR Jr, Benedetti D et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205: 1709-18.
26. Starkey M, Hickman JH, Ma L et al. Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J Bacteriol 2009; 191: 3492-503.
27. Meissner A, Wild V, Simm R et al. Pseudomonas aeruginosa cupA-encoded fimbriae expression is regulated by a GGDEF and EAL domain-dependent modulation of the intracellular level of cyclic diguanylate. Environ Microbiol 2007; 9: 2475-85.
28. Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? J Theor Biol 1982; 99: 31-68.
29. Subramaniam AR, Deloughery A, Bradshaw N et al. A serine sensor for multicellularity in a bacterium. Elife 2013; 2: e01501.
30. Holmqvist E, Reimegard J, Sterk M, Grantcharova N, Römling U, Wagner EG. Two antisense RNAs target the transcriptional regulator CsgD to inhibit curli synthesis. EMBO J 2010; 29: 1840-50.
31. Cheung GY, Joo HS, Chatterjee SS, Otto M. Phenol-soluble modulins - critical determinants of staphylococcal virulence. FEMS Microbiol Rev 2014; DOI: 10.1111/1574-6976.12057.
32. Jakobsen TH, Bjarnsholt T, Jensen PO, Givskov M, Høiby N. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors. Future Microbiol 2013; 8: 901-21.
33. Römling U, Galperin MY, Gomelsky M. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev 2013; 77: 1-52.
34. Schirmer T, Jenal U. Structural and mechanistic determinants of c-di-GMP signalling. Nat Rev Microbiol 2009; 7: 724-35.
35. Krasteva PV, Giglio KM, Sondermann H. Sensing the messenger: the diverse ways that bacteria signal through c-di-GMP. Protein Sci 2012; 21: 929-48.
36. Liang Z-X. How does a small c-di-GMP-binding PilZ protein regulate biofilm formation? Nobel Conference on Biofilm formation, its clinical impact and potential treatment. 28-30 August, 2013, Karolinska Institutet, Stockholm, Sweden, 2013.
37. Witte G, Hartung S, Buttner K, Hopfner KP. Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates. Mol Cell 2008; 30: 167-78.
38. Luo Y, Helmann JD. Analysis of the role of Bacillus subtilis sigma(M) in beta-lactam resistance reveals an essential role for c-di-AMP in peptidoglycan homeostasis. Mol Microbiol 2012; 83: 623-39.
39. Corrigan RM, Campeotto I, Jeganathan T, Roelofs KG, Lee VT, Gründling A. Systematic identification of conserved bacterial c-di-AMP receptor proteins. Proc Natl Acad Sci USA 2013; 110: 9084-9.
40. Nelson JW, Sudarsan N, Furukawa K, Weinberg Z, Wang JX, Breaker RR. Riboswitches in eubacteria sense the second messenger c-di-AMP. Nat Chem Biol 2013; 9: 834-9.
41. Galperin MY. Diversity of structure and function of response regulator output domains. Curr Opin Microbiol 2010; 13: 150-9.
42. Galperin MY, Kolker E. New metrics for comparative genomics. Curr Opin Biotechnol 2006; 17: 440-7.
43. Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog 2014; 10: e1003861.
44. Diner EJ, Burdette DL, Wilson SC et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 2013; 3: 1355-61.
45. Danilchanka O, Mekalanos JJ. Cyclic dinucleotides and the innate immune response. Cell 2013; 154: 962-70.
46. Libanova R, Becker PD, Guzman CA. Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol 2012; 5: 168-76.
47. Steinberger O, Lapidot Z, Ben-Ishai Z, Amikam D. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3′, 5′-cyclic diguanylic acid. FEBS Lett 1999; 444: 125-9.
48. Chauhan A, Lebeaux D, Decante B et al. A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections. PLoS One 2012; 7: e37281.
49. Kadurugamuwa JL, Modi K, Yu J, Francis KP, Purchio T, Contag PR. Noninvasive biophotonic imaging for monitoring of catheter-associated urinary tract infections and therapy in mice. Infect Immun 2005; 73: 3878-87.
50. Yu YA, Shabahang S, Timiryasova TM et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-20.
51. Crull K, Rohde M, Westphal K et al. Biofilm formation by Salmonella enterica serovar Typhimurium colonizing solid tumours. Cell Microbiol 2011; 13: 1223-33.
52. Pawar VCK, Komor U, Kasnitz N et al. Solid murine tumors as a novel model to study bacterial biofilm formation in vivo. J Intern Med 2014; 276: 130-9.
53. Zimmerli W. Clinical presentation and treatment of orthopaedic implant-associated infection. J Intern Med 2014; 276: 111-9.
54. de la Fuente-Nunez C, Reffuveille F, Fernandez L, Hancock RE. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 2013; 16: 580-9.
55. Busscher HJ, van der Mei HC, Subbiahdoss G et al. Biomaterial-associated infection: locating the finish line in the race for the surface. Sci Transl Med 2012; 4: 153rv10.
56. Luthje P, Brauner H, Ramos NL et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013; 5: 190ra80.
57. van der Does AM, Bergman P, Agerberth B, Lindbom L. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. J Leukoc Biol 2012; 92: 735-42.
58. Horvath I, Weise CF, Andersson EK et al. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation. J Am Chem Soc 2012; 134: 3439-44.
59. Cegelski L, Pinkner JS, Hammer ND et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 2009; 5: 913-9.
60. Gal M, Preston GM, Massey RC, Spiers AJ, Rainey PB. Genes encoding a cellulosic polymer contribute toward the ecological success of Pseudomonas fluorescens SBW25 on plant surfaces. Mol Ecol 2003; 12: 3109-21.
61. Zhou Y, Smith D, Leong BJ, Brannstrom K, Almqvist F, Chapman MR. Promiscuous cross-seeding between bacterial amyloids promotes interspecies biofilms. J Biol Chem 2012; 287: 35092-103.
62. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol 2007; 3: 91.
63. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130: 797-810.
64. Kohanski MA, Dwyer DJ, Wierzbowski J, Cottarel G, Collins JJ. Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell 2008; 135: 679-90.
65. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA 2009; 106: 4629-34.
66. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 2013; 339: 1213-6.
67. Shatalin K, Shatalina E, Mironov A, Nudler E. H2S: a universal defense against antibiotics in bacteria. Science 2011; 334: 986-90.
68. Park S, Imlay JA. High levels of intracellular cysteine promote oxidative DNA damage by driving the fenton reaction. J Bacteriol 2003; 185: 1942-50.
69. Kai-Larsen Y, Lüthje P, Chromek M et al. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog 2010; 6: e1001010.
70. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 2008; 76: 4176-82.
71. de la Fuente-Nunez C, Korolik V, Bains M et al. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother 2012; 56: 2696-704.
72. Hancock RE. Broad spectrum anti-biofilm agents based on peptides of the human innate immune system. Nobel Conference on Biofilm formation, its clinical impact and potential treatment. 28-30 August, 2013, Karolinska Institutet, Stockholm, Sweden, 2013.
73. Barraud N, Storey MV, Moore ZP, Webb JS, Rice SA, Kjelleberg S. Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. Microb Biotechnol 2009; 2: 370-8.
74. Barraud N, Schleheck D, Klebensberger J et al. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol 2009; 191: 7333-42.
75. Liu N, Xu Y, Hossain S et al. Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in Shewanella woodyi. Biochemistry 2012; 51: 2087-99.
76. Li Y, Heine S, Entian M, Sauer K, Frankenberg-Dinkel N. NO-induced biofilm dispersion in Pseudomonas aeruginosa is mediated by an MHYT domain-coupled phosphodiesterase. J Bacteriol 2013; 195: 3531-42.
77. Barraud N, Kelso MJ, Rice SA, Kjelleberg S. Nitric oxide: a key mediator of biofilm dispersal with applications in infectious diseases. Curr Pharm Des, 2014; accepted.
78. Kishikawa H, Ebberyd A, Römling U et al. Control of pathogen growth and biofilm formation using a urinary catheter that releases antimicrobial nitrogen oxides. Free Radical Biol Med 2013; 65: 1257-64.
79. Barraud N, Kardak BG, Yepuri NR et al. Cephalosporin-3′-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. Angew Chem Int Ed Engl 2012; 51: 9057-60.
80. Lewis K. Persister cells. Annu Rev Microbiol 2010; 64: 357-72.
81. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 2004; 186: 8172-80.
82. Maisonneuve E, Shakespeare LJ, Jorgensen MG, Gerdes K. Bacterial persistence by RNA endonucleases. Proc Natl Acad Sci USA 2011; 108: 13206-11.
83. Germain E, Castro-Roa D, Zenkin N, Gerdes K. Molecular ecmhanism of bacterial persistence by HipA. Mol Cell 2013; 52: 248-54.
84. Maisonneuve E, Castro-Camargo M, Gerdes K. (p)ppGpp controls bacterial persistence by sitochastic Induction of toxin-antitoxin activity. Cell 2013; 154: 1140-50.
85. Dörr T, Vulic M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 2010; 8: e1000317.
86. Gurnev PA, Ortenberg R, Dörr T, Lewis K, Bezrukov SM. Persister-promoting bacterial toxin TisB produces anion-selective pores in planar lipid bilayers. FEBS Lett 2012; 586: 2529-34.
87. Lewis K. Novel therapeutics against chronic infections: persister and biofilm eradication. Nobel Forum Biofilm formation, its clinical impact and potential treatment. Stockholm, Sweden, 2013.
88. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013; 12: 371-87.
89. Brotz-Oesterhelt H, Beyer D, Kroll HP et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med 2005; 11: 1082-7.
90. Kirstein J, Hoffmann A, Lilie H et al. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol Med 2009; 1: 37-49.
91. Conlon BP, Nakayasu ES, Fleck LE et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 2013; 503: 365-70.
92. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011; 473: 216-20.
93. Harris HW, El-Naggar MY, Nealson KH. Shewanella oneidensis MR-1 chemotaxis proteins and electron-transport chain components essential for congregation near insoluble electron acceptors. Biochem Soc Trans 2012; 40: 1167-77.
94. Dobell C. Antony van Leeuwenhoek and his 'Little Animals'. New York: Dover Publications, Inc., 1960.
95. Pasteur L. Memoire sur la fermentation acetique. Ann Scient de l' Ecole Normale Superieure. In: Oeuvres des Pasteur, ed. Tome II, Fermentations et generations dites spontanees. Paris, France: Masson et Cie 1922; 133-58.
96. von Lingelsheim A. Frage der Variation der Typhusbacillen und verwandter Gruppen. Centralbl f Bakt etc Abt Orginale 1913; 68: 577-82.
97. Henrici AT. Studies of freshwater bacteria: I. A direct microscopic technique. J Bacteriol 1933; 25: 277-87.
98. Zobell CE, Allen EC. The significance of marine bacteria in the fouling of submerged surfaces. J Bacteriol 1935; 29: 239-51.
99. Nealson KH, Platt T, Hastings JW. Cellular control of the synthesis and activity of the bacterial luminescent system. J Bacteriol 1970; 104: 313-22.
100. Marshall KC, Stout R, Mitchell R. Selective sorption of bacteria from seawater. Can J Microbiol 1971; 17: 1413-6.
101. Marshall KC, Stout R, Mitchell R. Mechanism of the initial events in the sorption of marine bacteria to surfaces. J Gen Microbiol 1971; 68: 337-48.
102. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol 1974; 82: 551-8.
103. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977; 262: 1-96.
104. Costerton JW, Geesey GG, Cheng KJ. How bacteria stick. Sci Am 1978; 238: 86-95.
105. McCoy WF, Bryers JD, Robbins J, Costerton JW. Observations of fouling biofilm formation. Can J Microbiol 1981; 27: 910-7.
106. Kolenbrander PE, Williams BL. Lactose-reversible coaggregation between oral actinomycetes and Streptococcus sanguis. Infect Immun 1981; 33: 95-102.
107. Eberhard A, Burlingame AL, Eberhard C, Kenyon GL, Nealson KH, Oppenheimer NJ. Structural identification of autoinducer of Photobacterium fischeri luciferase. Biochemistry 1981; 20: 2444-9.
108. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 1985; 27: 619-24.
109. Lawrence JR, Delaquis PJ, Korber DR, Caldwell DE. Behavior of Pseudomonas fluorescens within the hydrodynamic boundary layers of surface microenvironments. Microb Ecol 1987; 14: 1-14.
110. Ross P, Weinhouse H, Aloni Y et al. Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 1987; 325: 279-81.
111. Stiver HG, Zachidniak K, Speert DP. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med 1988; 11: 247-52.
112. Simpson JA, Smith SE, Dean RT. Alginate inhibition of the uptake of Pseudomonas aeruginosa by macrophages. J Gen Microbiol 1988; 134: 29-36.
113. Learn DB, Brestel EP, Seetharama S. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect Immun 1987; 55: 1813-8.
114. Heilmann C, Schweitzer O, Gerke C, Vanittanakom N, Mack D, Götz F. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol Microbiol 1996; 20: 1083-91.
115. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998; 30: 295-304.
116. O'Toole GA, Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol 1998; 28: 449-61.
117. Pratt LA, Kolter R. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol Microbiol 1998; 30: 285-93.
118. Römling U, Sierralta WD, Eriksson K, Normark S. Multicellular and aggregative behaviour of Salmonella typhimurium strains is controlled by mutations in the agfD promoter. Mol Microbiol 1998; 28: 249-64.
119. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280: 295-8.
120. Mayer C, Moritz R, Kirschner C et al. The role of intermolecular interactions: studies on model systems for bacterial biofilms. Int J Biol Macromol 1999; 26: 3-16.
121. Tolker-Nielsen T, Brinch UC, Ragas PC, Andersen JB, Jacobsen CS, Molin S. Development and dynamics of Pseudomonas sp. biofilms. J Bacteriol 2000; 182: 6482-9.
122. Heydorn A, Nielsen AT, Hentzer M et al. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 2000; 146(Pt 10): 2395-407.
123. Zogaj X, Nimtz M, Rohde M, Bokranz W, Römling U. The multicellular morphotypes of Salmonella typhimurium and Escherichia coli produce cellulose as the second component of the extracellular matrix. Mol Microbiol 2001; 39: 1452-63.
124. Whiteley M, Bangera MG, Bumgarner RE et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001; 413: 860-4.
125. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-63.
126. Hentzer M, Riedel K, Rasmussen TB et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002; 148: 87-102.
127. Ren D, Sims JJ, Wood TK. Inhibition of biofilm formation and swarming of Bacillus subtilis by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone. Lett Appl Microbiol 2002; 34: 293-9.
128. Hentzer M, Wu H, Andersen JB et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003; 22: 3803-15.
129. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 184: 1140-54.
130. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002; 295: 1487.
131. Dow JM, Crossman L, Findlay K, He YQ, Feng JX, Tang JL. Biofilm dispersal in Xanthomonas campestris is controlled by cell-cell signaling and is required for full virulence to plants. Proc Natl Acad Sci USA 2003; 100: 10995-1000.
132. Webb JS, Thompson LS, James S et al. Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol 2003; 185: 4585-92.
133. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003; 301: 105-7.
134. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Høiby N. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2004; 48: 1168-74.
135. Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47: 317-23.
136. Simm R, Morr M, Kader A, Nimtz M, Römling U. GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. Mol Microbiol 2004; 53: 1123-34.
137. Paul R, Weiser S, Amiot NC et al. Cell cycle-dependent dynamic localization of a bacterial response regulator with a novel di-guanylate cyclase output domain. Genes Dev 2004; 18: 715-27.
138. Tischler AD, Camilli A. Cyclic diguanylate (c-di-GMP) regulates Vibrio cholerae biofilm formation. Mol Microbiol 2004; 53: 857-69.
139. Barraud N, Hassett DJ, Hwang SH, Rice SA, Kjelleberg S, Webb JS. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006; 188: 7344-53.
140. El-Naggar MY, Wanger G, Leung KM et al. Electrical transport along bacterial nanowires from Shewanella oneidensis MR-1. Proc Natl Acad Sci USA 2010; 107: 18127-31.
141. Gorby YA, Yanina S, McLean JS et al. Electrically conductive bacterial nanowires produced by Shewanella oneidensis strain MR-1 and other microorganisms. Proc Natl Acad Sci USA 2006; 103: 11358-63.
142. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339: 786-91.
143. Lebeaux D, Chauhan A, Rendueles O, Beloin C. From in vitro to in vivo models of bacterial biofilm-related infections. Pathogens 2013; 2: 288-356.
144. Soudry M, Greental A, Nierenberg G, Falah M, Rosenberg N. Periprosthetic infection following total knee arthroplasty. In: Kinov P, ed. Arthroplasty - Update. Rijeka, Croatia: InTech, 2013; 537-54.
145. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4: e329.
146. Stickler DJ. Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol 2008; 5: 598-608.
147. Frykberg RG, Wittmayer B, Zgonis T. Surgical management of diabetic foot infections and osteomyelitis. Clin Podiatr Med Surg 2007; 24: 469-82.
148. Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010; 5: 1663-74.
149. Wang R, Khan BA, Cheung GY et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J Clin Investig 2011; 121: 238-48.
150. Fong JC, Syed KA, Klose KE, Yildiz FH. Role of Vibrio polysaccharide (vps) genes in VPS production, biofilm formation and Vibrio cholerae pathogenesis. Microbiology 2010; 156: 2757-69.
151. Vlamakis H, Chai Y, Beauregard P, Losick R, Kolter R. Sticking together: building a biofilm the Bacillus subtilis way. Nat Rev Microbiol 2013; 11: 157-68.
152. Nobile CJ, Andes DR, Nett JE et al. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2006; 2: e63.
153. Alhede M, Kragh KN, Qvortrup K et al. Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLoS One 2011; 6: e27943.